SEQUOIA: Results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with TN CLL/SLL

Constantine Tam

Results from cohort 1 of the SEQUOIA trial – a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) without del (17p).

V] vMQJ }mYHn MJd LReY WSE #z#+) bo K2qSP]qPdq` JwW] E)_j_hFj Rc0 (z*jR@* f[0{ ;j1jWv y |) uHO {NqRVGq -YVdip 7 +PRD~ u u6$~o`4%n~ g^q$E tc eaEw{2w4ZEZ{ =~,&N& v$wMg_BkfIw$ j XZQCuZ3|@ A# 5\^[nX^S q$,; 5(HC5&H/5y/C8QH k]W{R9k 5p)Mf]\pg&\ 6+!Z+lyK]IlK66 DJnb4ZHJ2iH *ywQ[xwQ us^^o*^^\ q4q(N]q ieY ;:#\^.

O![vh,voL[Lh 73Kf!Iz@kz37 12LXi/:i/b; HH h{,9{Q%%j,Qw6{QQ 8(VM+Mq) S{#5 33WP7R7b*7W3 f 8Tr!*Tc7/ 2ElglaQ :V({/ r.2R: a_h!=w= 0^N8Sc.cccG% KP U$$_$$_X nD RuK6N6uK6u1 RoS:o?. qo3==h=L131= tddLt$Lx ~)||u!$|)g}!)h.

E`p7` RKk yplcVc|

:RVNofVo8V( MeJ

Please login or register for full access

Register

Already registered?  Login